MEN1703

MEN1703 (SEL24) is a small molecule (kinase inhibitor) developed by Ryvu Therapeutics. Its target is FLT3 (the sponsor names PIM/FLT3 kinase). ClinicalTrials.gov describes the intervention as: MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukaemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT06534437, plans to enrol 178 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.